US FDA Biologics Group Emerging From Pandemic Footing – But Not Vaccines

The COVID-19 pandemic is definitely not over when it comes to the workload facing the US FDA’s vaccine review team, even as the other biologics review operations get back ‘toward normal.’

post- COVID-19 road
• Source: Shutterstock

The US Food & Drug Administration’s vaccine review operations are still not close to returning to pre-pandemic levels of operations, Center for Biologics Evaluation & Research Director Peter Marks said during a Reagan-Udall Foundation/Friends of Cancer Research event.

“In the area of vaccines, we are still very much under a very large load of work,” Marks said. “Vaccines are not in any way shape or form [back to] routine, every day” status

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.